NO20055838D0 - Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav - Google Patents

Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav

Info

Publication number
NO20055838D0
NO20055838D0 NO20055838A NO20055838A NO20055838D0 NO 20055838 D0 NO20055838 D0 NO 20055838D0 NO 20055838 A NO20055838 A NO 20055838A NO 20055838 A NO20055838 A NO 20055838A NO 20055838 D0 NO20055838 D0 NO 20055838D0
Authority
NO
Norway
Prior art keywords
binding protein
medical applications
active variants
active fragments
active
Prior art date
Application number
NO20055838A
Other languages
English (en)
Other versions
NO338682B1 (no
NO20055838L (no
Inventor
Valter Altarocca
Anna R Pezzotti
Original Assignee
Applied Research Systems
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Applied Research Systems filed Critical Applied Research Systems
Publication of NO20055838D0 publication Critical patent/NO20055838D0/no
Publication of NO20055838L publication Critical patent/NO20055838L/no
Publication of NO338682B1 publication Critical patent/NO338682B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/215—IFN-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
NO20055838A 2003-05-13 2005-12-08 IL-18 bindingsprotein (IL-18BP), en sammensetning, fremgangsmåte for fremstilling samt anvendelse NO338682B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP03101326 2003-05-13
PCT/EP2004/005073 WO2004101617A1 (en) 2003-05-13 2004-05-11 Active variants of the il-18 binding protein and medical uses thereof

Publications (3)

Publication Number Publication Date
NO20055838D0 true NO20055838D0 (no) 2005-12-08
NO20055838L NO20055838L (no) 2006-02-13
NO338682B1 NO338682B1 (no) 2016-09-26

Family

ID=33442815

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055838A NO338682B1 (no) 2003-05-13 2005-12-08 IL-18 bindingsprotein (IL-18BP), en sammensetning, fremgangsmåte for fremstilling samt anvendelse

Country Status (16)

Country Link
US (2) US20080076708A1 (no)
EP (1) EP1622939B1 (no)
JP (1) JP5074030B2 (no)
AT (1) ATE549353T1 (no)
AU (1) AU2004238524B2 (no)
CA (1) CA2524403C (no)
CY (1) CY1112682T1 (no)
DK (1) DK1622939T3 (no)
ES (1) ES2384241T3 (no)
HR (1) HRP20120246T1 (no)
IL (1) IL171914A (no)
NO (1) NO338682B1 (no)
PL (1) PL1622939T3 (no)
PT (1) PT1622939E (no)
SI (1) SI1622939T1 (no)
WO (1) WO2004101617A1 (no)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ520392A (en) * 2000-02-10 2005-04-29 Abbott Lab Antibodies that bind human interleukin-18 and methods of making and using
KR101180139B1 (ko) 2003-03-11 2012-09-13 메르크 세로노 에스.에이. Ｍｃｍｖ ｉｅ2 프로모터를 포함하는 발현 벡터
CA2541523A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
CA2544146C (en) * 2003-11-05 2012-10-02 Ares Trading S.A. Process for the purification of il-18 binding protein
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
DK1720979T3 (da) 2004-03-01 2007-12-10 Ares Trading Sa Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller
US7557084B2 (en) 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
AU2005259269B2 (en) 2004-06-29 2010-12-09 Ares Trading S.A. Process for the purification of IL-18 binding protein
ATE557038T1 (de) 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
US8128920B2 (en) 2005-06-03 2012-03-06 Merck Serono Sa Use of IL-18BP isoforms for the treatment and/or prevention of neurological inflammatory diseases
EP1891088B1 (en) * 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein
CN103228290A (zh) 2011-02-18 2013-07-31 (株)斯坦帝尔 包含沉默信息调节因子1表达诱导物质的败血症或者败血性休克的预防或者治疗用组合物
JOP20200308A1 (ar) 2012-09-07 2017-06-16 Novartis Ag جزيئات إرتباط il-18
EP3041864B1 (en) * 2013-09-05 2021-07-21 AB2 Bio SA Il-18 binding protein (il-18bp) in inflammatory diseases
AU2016227644B2 (en) 2015-03-05 2022-06-16 Ab2 Bio Sa IL-18 Binding Protein (IL-18BP) and antibodies in inflammatory diseases
CN111315395A (zh) * 2017-09-06 2020-06-19 耶鲁大学 白细胞介素-18变体和使用方法
CN114605521A (zh) * 2022-04-06 2022-06-10 内蒙古农业大学 一种细胞免疫调节蛋白及其应用

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) * 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
IL121860A0 (en) * 1997-08-14 1998-02-22 Yeda Res & Dev Interleukin-18 binding proteins their preparation and use
CA2340579A1 (en) * 1998-09-01 2000-03-09 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interleukin 18-binding protein
JP4216950B2 (ja) * 1998-09-01 2009-01-28 株式会社林原生物化学研究所 インターロイキン−１８結合蛋白質
PT1278540E (pt) 2000-05-05 2008-07-03 Inst Nat Sante Rech Med Utilização de inibidores da il-18 para o tratamento e/ou prevenção de aterosclerose
WO2002032374A2 (en) * 2000-10-18 2002-04-25 Immunex Corporation Methods for treating il-18 mediated disorders
DE60224004T2 (de) 2001-01-29 2009-07-23 Laboratoires Serono S.A., Coinsins Verwendung von il-18 hemmern zur behandlung und/oder prävention von herzkrankheiten
US20030008822A1 (en) 2001-05-16 2003-01-09 Charles Dinarello Use of IL-18 inhibitors for the treatment or prevention of sepsis
HU230294B1 (hu) 2001-05-25 2015-12-28 Ares Trading S.A. IL-18-inhibitorok alkalmazása központi idegrendszeri sérülések kezelésére vagy megelőzésére
JP2005505608A (ja) 2001-10-11 2005-02-24 アプライド・リサーチ・システムズ・エイアールエス・ホールディング・ナムローゼ・フェンノートシャップ 糖尿病性神経障害でのｇｐ１３０アクチベーターの使用法
KR101180139B1 (ko) * 2003-03-11 2012-09-13 메르크 세로노 에스.에이. Ｍｃｍｖ ｉｅ2 프로모터를 포함하는 발현 벡터
CA2541523A1 (en) * 2003-10-21 2005-05-06 Applied Research Systems Ars Holding N.V. Minimal dna sequence acting as a chromatin insulator and its use in protein expression
CA2544146C (en) * 2003-11-05 2012-10-02 Ares Trading S.A. Process for the purification of il-18 binding protein
DK1720979T3 (da) * 2004-03-01 2007-12-10 Ares Trading Sa Anvendelse af et serumfrit celledyrkningsmedium til fremstilling af IL-18BP I pattedyrceller
US7557084B2 (en) * 2004-03-31 2009-07-07 Regeneron Pharmaceuticals, Inc. IL-18 specific polypeptides and therapeutic uses thereof
AU2005259269B2 (en) * 2004-06-29 2010-12-09 Ares Trading S.A. Process for the purification of IL-18 binding protein
ATE557038T1 (de) * 2005-06-03 2012-05-15 Ares Trading Sa Herstellung von rekombinantem il-18 bindendem protein
EP1891088B1 (en) * 2005-06-10 2011-10-19 Ares Trading S.A. Process for the purification of il-18 binding protein

Also Published As

Publication number Publication date
JP2007535903A (ja) 2007-12-13
PL1622939T3 (pl) 2012-08-31
DK1622939T3 (da) 2012-04-10
CA2524403A1 (en) 2004-11-25
PT1622939E (pt) 2012-03-28
AU2004238524A1 (en) 2004-11-25
IL171914A0 (en) 2006-04-10
ATE549353T1 (de) 2012-03-15
NO338682B1 (no) 2016-09-26
AU2004238524B2 (en) 2011-06-23
EP1622939A1 (en) 2006-02-08
JP5074030B2 (ja) 2012-11-14
CY1112682T1 (el) 2016-02-10
NO20055838L (no) 2006-02-13
ES2384241T3 (es) 2012-07-02
HRP20120246T1 (hr) 2012-04-30
SI1622939T1 (sl) 2012-06-29
EP1622939B1 (en) 2012-03-14
US20110189131A1 (en) 2011-08-04
WO2004101617A1 (en) 2004-11-25
US20080076708A1 (en) 2008-03-27
IL171914A (en) 2013-05-30
CA2524403C (en) 2013-07-09

Similar Documents

Publication Publication Date Title
NO20055838D0 (no) Aktive varianter av IL-18 bindende protein og medisinske anvendelser derav
SE0301700D0 (sv) Novel compounds
ATE350409T1 (de) Ampholytisches copolymer und dessen verwendung
NO20085338L (no) Substituerte 1,3-difenylpropanderivater, sammensetninger og anvendelser derav
DK1490062T3 (da) Glukokortikoidmimetika, fremgangsmåder til fremstilling deraf, farmaceutiske sammensætninger og anvendelser deraf
WO2004103208A3 (en) Manufacture and use of implantable reticulated elastomeric matrices
WO2003101401A3 (en) Use of nrg4, or inhibitors thereof, in the treatment of colon and pancreatic cancer
NO20070130L (no) Farmasoytiske sammensetninger
MX2010003574A (es) Anticuerpos il-23.
UA87335C2 (en) Gel composition of 4-hydroxytamoxifen
TW200505875A (en) Novel compounds
NO20083245L (no) Sykliske antimikrobielle peptider
NO20043441L (no) Orodispersibel farmasoytisk sammensetning omfattende agomelatin
CY1109361T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
CY1113116T1 (el) Υποκατεστημενες 4-αμινοκυκλοεξανολες
EA200600403A1 (ru) Препараты кладрибина для улучшенной пероральной доставки и доставки через слизистые оболочки
BRPI0411485A (pt) peptìdeo derivado de rasgap para matar seletivamente células cancerosas
ATE355104T1 (de) Haarbehandlungsmittel
SE0102716D0 (sv) Novel compounds
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
ITRM20030363A1 (it) Composizioni comprendenti la 3, 5diiodotironina e uso farmaceutico di esse.
DE602006020155D1 (de) Pharmazeutische wundheilungs-zusammensetzungen in ren und natriumhyaluronat
WO2007134118A3 (en) Protein based composition and methods of using same
SE0300457D0 (sv) Novel compounds
WO2006023465A8 (en) Polyethylene glycol-peptide copper complexes and compositions and methods related thereto

Legal Events

Date Code Title Description
CREP Change of representative

Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS

CREP Change of representative

Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO